<DOC>
	<DOC>NCT01000818</DOC>
	<brief_summary>An open-label, 3-period, fixed-sequence study in a panel of 18 HIV-infected patients on MK0518 as part of a stable treatment regimen for HIV.</brief_summary>
	<brief_title>A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patient is Human immunodeficiency virus (HIV) positive Patient is taking an MK0518 (Raltegravir) containing regimen Patient has not had any changes to his/her antiviral regimen in the last 2 weeks Patient who is of reproductive potential agrees to use an acceptable method of birth control Patients baseline health is stable Patient has a history of stroke or chronic seizures. Patient has a history of gastric bypass surgery Patient is pregnant of breastfeeding Patient consumes excessive amounts of caffeinated beverages daily Patient has had major surgery, donated blood, or participated in another investigational study in the past 4 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Treatment experienced</keyword>
</DOC>